Previous 10 | Next 10 |
2023-07-24 19:15:20 ET Summary Curis, a microcap biotech company, is focusing on the development of cancer drugs, currently supporting six drug trials with a burn rate of over $30 million per year. Despite a recent direct offering adding $15.1 million to its balance sheet and a lo...
2023-07-06 08:55:06 ET Biotechnology company Curis ( NASDAQ: CRIS ) said on Thursday that it is launching an ~$15.1M registered direct offering priced at-the-market. The company has entered into definitive agreements led by existing investors for the purchase of 18.4M shares a...
2023-07-06 08:27:17 ET Curis, Inc. ( NASDAQ: CRIS ) announced Thursday that the FDA removed the partial clinical hold placed on the company’s Phase 1/2 TakeAim Leukemia trial for lead candidate emavusertib. The trial is targeted at patients with acute myeloid leukemia (AM...
FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID PR Newswire LEXINGTON, Mass. , July 6, 2023 /PRNewswire/ -- Curis, Inc., (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, an orally availa...
Curis Announces $15.1 Million Registered Direct Offering PR Newswire LEXINGTON, Mass. , July 6, 2023 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, a triple target inhibitor (IRAK4, FLT3 an...
2023-05-04 21:59:06 ET Curis, Inc. (CRIS) Q1 2023 Earnings Conference Call May 04, 2023, 04:30 PM ET Company Participants Diantha Duvall - Chief Financial Officer James Dentzer - President and Chief Executive Officer Robert Martell - Chief Scientific Officer ...
2023-05-04 16:48:16 ET Curis press release ( NASDAQ: CRIS ): Q1 GAAP EPS of -$0.12 misses by $0.01 . Revenue of $2.3M (+11.7% Y/Y) misses by $0.29M . For further details see: Curis GAAP EPS of -$0.12 misses by $0.01, revenue of $2.3M misses by $0.29M
Curis Provides First Quarter 2023 Business Update PR Newswire Company expects to discuss lifting of partial clinical hold on emavusertib with FDA in Q3 Curis strengthens executive team with appointment of industry veteran Jonathan Zung , Ph.D. as Chief Development ...
Curis to Release First Quarter 2023 Financial Results and Hold Conference Call on May 4, 2023 PR Newswire LEXINGTON, Mass. , April 27, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics f...
2023-04-06 05:20:37 ET Curis ( NASDAQ: CRIS ) said a new employee will be granted stock options to buy 135.45K common shares of the company. The inducement grant has an exercise price equal to the closing price of the common stock on March 31, the company added. The s...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis to Present at Upcoming Healthcare Conference in July PR Newswire LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IR...
2024-05-25 08:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...